Tatva Chintan Pharma Chem Limited

As of June 30, 2026, Tatva Chintan Pharma Chem Limited carries a market capitalization of 27.84B, placing it among publicly traded companies globally. Its enterprise value stands at 27.84B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Tatva Chintan Pharma Chem Limited's next confirmed earnings release is scheduled for January 21, 2027.

As of June 30, 2026, Tatva Chintan Pharma Chem Limited has 23.39M shares outstanding.

As of June 30, 2026, Tatva Chintan Pharma Chem Limited trades at a trailing price-to-earnings ratio of 54.17.

As of June 30, 2026, Tatva Chintan Pharma Chem Limited trades at an EV/EBITDA multiple of 26.06 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.01 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 40.72 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 27.84B versus a market cap of 27.84B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 5.46M in revenue per employee across its workforce of 1,018.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Tatva Chintan Pharma Chem Limited recorded 176.35M in income tax expense. That works out to an effective tax rate of 25.55, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 690.19M, leaving 513.84M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Tatva Chintan Pharma Chem Limited's stock has gained approximately 17.89% over the past 52 weeks. The 50-day moving average sits at 1,731.66, while the 200-day moving average is 1,393.65.

Over the twelve months ended June 30, 2026, Tatva Chintan Pharma Chem Limited generated 5.56B in revenue and converted that into 513.84M in net income, yielding earnings per share of 21.97. EBITDA reached 1.07B, while operating income came in at 696.82M.

Over the twelve months ended June 30, 2026, Tatva Chintan Pharma Chem Limited posted a gross margin of 56.57, reflecting its pricing power and cost economics. The operating margin of 12.53 and net profit margin of 9.24 provide insight into operational efficiency.